Anticancer agent 3

Anticancer agent 3 (Compound 4) is an anticancer agent.

Anticancer agent 30 (compound 6f-Z) is a potent 3-arylidene-2-oxindole derivative that acts as a selective CDK2 inhibitor, showing significant anticancer activity and potential as a cancer treatment [1].

Anticancer agent 33 (compound 3), derived from Squamocin and Bullatacin, exhibits potent inhibitory activity against the 4T1 breast cancer cell line (A549, HeLa, HepG2, and MCF-7 cells) with IC50 values ranging from 1.9 to 5.4 µM [1].

Anticancer agent 38 (compound 19) is an aryl-urea compound, and is a potent anticancer agent. Anticancer agent 38 inhibits A431 cell growth with an IC 50 of 5.2 μg mL [1].

Anticancer agent 37 (compound 18) is a sulfonylurea derivative known for its potent anticancer activity. It efficiently inhibits the growth of HePG2 cells, displaying an IC 50 value of 17.2 μg mL [1].

Anticancer agent 35 (compound 10), a sulfonylurea derivative, is a potent anticancer agent that inhibits A549, A431, and PACA2 cell growth with IC50 values of 18.1 μg mL, 4.0 μg mL, and 18.9 μg mL, respectively [1].

Anticancer agent 36 (compound 11) is a potent anti-microbial and anti-cancer agent, a sulfonylurea derivative. anticancer agent 36 inhibits the microbial growth of Bacillus mycoides, Escherichia coli and Candida albicans (MIC: 0.156 - 0.039 mg mL). Anticancer agent 36 inhibited the growth of A549 cells (IC50: 19.7 μg mL), PC3 cells (IC50: 11.9 μg mL).

Anticancer agent 32 (compound 2g) is an anticancer compound that affects the cell cycle and induces apoptosis, making it valuable for cancer research.

Anticancer agent 34 (compound 9) is a sulfonylurea derivative and a potent anti-microbial and anti-cancer agent. anticancer agent 34 showed inhibition of microbial growth of Mycobacterium, Escherichia coli and Candida albicans (MIC: 0.039-0.156 mg ml). Anticancer agent 34 inhibited the growth of A549 cells (IC50: 8.4 μg ml), PC3 cells (IC50: 7.8 μg ml).

Anticancer agent 31 is an anticancer agent, a 1,3-diphenylurea quinoxaline derivative. anticancer agent 31 exhibits antitumor effects by blocking the cell cycle in S phase and inducing apoptosis.

Anticancer Agent 39 (compound B12), a fluorescent derivative of Jiyuan Oridonin A (JOA), not only induces apoptosis through the collapse of mitochondrial membrane potential (MMP) but also inhibits cell cloning and migration, demonstrating promising anti-proliferative activity against HGC-27 cells with an IC50 value of 0.39 μM [1].

1. Octyl Gallate is an antioxidant approved by the US Food and Drug Administration (FDA) as a food additive. 2. Octyl Gallate has antimetastatic activity. 3. Octyl Gallate shows antimicrobial activity against H. pylori, with a minimum inhibitory concentration (MIC) value of 125 ug mL. 4. Combination therapy with octyl gallate and ferulic acid improves cognition and neurodegeneration in a transgenic mouse model of Alzheimer's disease.5. Octyl Gallate is a potential anticancer agent, it exhibited decreased MCF-7 & MDA-MB-231 survival and induced apoptosis, with IC50 value of 40 uM. 6. Octyl gallate (Octyl 3,4,5-trihydroxybenzoate) has antiviral activity, it shows an inhibitory effect on the growth of herpes simplex virus type 1 (HSV-1) in HEp-2 or Vero cells. 7. Octyl gallate shows antifungal activity against Saccharomyces cerevisiae ATCC7754 and Zygosaccharomyces bailii ATCC 60483.

1. Cinnamaldehyde (Cinnamic Aldehyde) has antipyretic activity. 2. Cinnamaldehyde is a sedative agent. 3. Cinnamaldehyde inhibits invasive capabilities of MDA-MB-435S cells was correlated with down-regulating the expression of miR-27a. 4. Cinnamaldehyde induces the generation of reactive oxygen species and exerts vasodilator and anticancer effects. 5. Cinnamaldehyde appears to be a promising candidate as an adjuvant in combination therapy with 5-fluorouracil (5-FU) and oxaliplatin (OXA), two chemotherapeutic agents used in CRC treatment. The possible mechanisms of its action may involve the regulation of drugmetabolizing genes. 6. Cinnamaldehyde plays a certain role in inhibiting the occurrence and progression of melanoma and its action mechanism may be manifested by inhibiting expression of VEGF and HIF-α, thus blood vessel simulation and formation of new blood vessels of melanoma cells, and growth of tumors accordingly.

4-Bromo-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione has potential as an anticancer, prodrug for the treatment of Parkinson's disease, and as an anti-inflammatory agent.

1. 3-Dehydrotrametenolic acid can be a potential anticancer agent against H-ras transformed tumor. 2. Dehydrotrametenolic acid is a promising candidate for a new type of insulin-sensitizing drug.

Anticancer agent 43 is a potent anticancer agent that induces apoptosis through caspase 3, PARP1, and Bax protein-dependent pathways.Anticancer agent 43 induces DNA damage and can be used in the study of glioblastoma in rats.

MNK8 (3-methyl-6-(naphthalen-1-yl)pyrimidine-2,4(1H,3H)-dione) is a potent STAT3 inhibitor that reduces the ability of STAT3 to bind to DNA and also has a good growth inhibition effect on liver cancer cells [1].

Multi-target kinase inhibitor 3 (compound 6i) is a potent multi-target anticancer agent.

Antiangiogenic agent 7 (Compound 1) induces apoptosis, elevates Reactive Oxygen Species (Reactive Oxygen Species), and inhibits the intracellular enzyme thioredoxin reductase. It exhibits anticancer activity with IC50 values ranging from 0.08 to 3.5 μM against cervical cancer cells (HeLa), prostate cancer cells (PC-3), and non-small cell lung cancer cells (A549). Additionally, Antiangiogenic agent 7 suppresses tumor growth in a mouse xenograft model.

Antitumor agent-196 (Compound 6a (β, β, β)) is an artemisinin-based oligomer with anticancer properties, exhibiting an IC50 of 90 nM against MCF-7 breast cancer cells. This compound induces apoptosis by modulating the Bax-caspase 3 signaling pathway and triggers ferroptosis by regulating key signaling molecules (including GPX4). Antitumor agent-196 shows potential for cancer research applications.

MDK-4204, an anticancer agent, shows significant anti-cancer activity with IC50 values of 8.8 µM and 9.5 µM in PC-3 and DU-145 cells, respectively.

2-deoxy-D-Glucose-13C6is intended for use as an internal standard for the quantification of 2-deoxy-D-glucose by GC- or LC-MS. 2-deoxy-D-Glucose is a glucose antimetabolite and an inhibitor of glycolysis.1,2It inhibits hexokinase, the enzyme that converts glucose to glucose-6-phosphate, as well as phosphoglucose isomerase, the enzyme that converts glucose-6-phosphate to fructose-6-phosphate.32-deoxy-D-Glucose (16 mM) induces apoptosis in SK-BR-3 cells, as well as inhibits the growth of 143B osteosarcoma cells cultured under hypoxic conditions when used at a concentration of 2 mg ml.4,5In vivo, 2-deoxy-D-glucose (500 mg kg) reduces tumor growth in 143B osteosarcoma and MV522 non-small cell lung cancer mouse xenograft models when used alone or in combination with doxorubicin or paclitaxel .6 1.Kang, H.T., and Hwang, E.S.2-Deoxyglucose: An anticancer and antiviral therapeutic, but not any more a low glucose mimeticLife Sci.78(12)1392-1399(2006) 2.Aft, R.L., Zhang, F.W., and Gius, D.Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: Mechanism of cell deathBr. J. Cancer87(7)805-812(2002) 3.Ralser, M., Wamelink, M.M., Struys, E.A., et al.A catabolic block does not sufficiently explain how 2-deoxy-D-glucose inhibits cell growthProc. Natl. Acad. Sci. USA105(46)17807-17811(2008) 4.Liu, H., Savaraj, N., Priebe, W., et al.Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: A strategy for solid tumor therapy (Model C)Biochem. Pharmacol.64(12)1745-1751(2002) 5.Zhang, X.D., Deslandes, E., Villedieu, M., et al.Effect of 2-deoxy-D-glucose on various malignant cell lines in vitroAnticancer Res.26(5A)3561-3566(2006) 6.Maschek, G., Savaraj, N., Priebe, W., et al.2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivoCancer Res.64(1)31-34(2004)

Phosphoramide mustard cyclohexanamine is the active metabolite of cyclophosphamide, an alkylating agent that cross-links DNA strands, organizes cell division and causes cell death, and has antitumor activity.

1. (+)-(3R,8S)-Falcarindiol is a potential new anticancer agent that exerts its activity through inducing ER stress and apoptosis. 2. Falcarindiol induces immunosuppressive effects in vitro and in vivo and might be a novel therapy for autoimmune or allergic diseases. 3. Falcarindiol has protective effect against CCl(4) toxicity , in part, be explained by anti-lipid peroxidation activity associated with the induction of the GSTs including GSTA4.